Evidence map›Paper›PMID 31119106›Full record

ArticleFrontiers in cellular and infection microbiology2019

A Multi-Stage

Jessica N McCaffery, Jairo A Fonseca, Balwan Singh, Monica Cabrera-Mora, Caitlin Bohannon, Joshy Jacob, Myriam Arévalo-Herrera, Alberto Moreno

Expression of concernOpen access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase inFrontiers in cellular and infection microbiology · 2024
    Article
  6. Article
  7. A multivalentBioengineering & translational medicine · 2023
    Article
  8. Article
  9. Frontiers in immunology · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jessica N McCafferyEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Jairo A FonsecaEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Balwan SinghEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Monica Cabrera-MoraEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Caitlin BohannonEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Joshy JacobEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Myriam Arévalo-HerreraCaucaseco Scientific Research Center, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Alberto MorenoEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Emory University · USCaucaseco Scientific Research Center · CO

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Optimization of chimeric multi-stage immunogens for malaria vaccine developmentR56AI103382 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2014 to 2014
$844k
Chimeric hybrid transmission blocking vaccine for malariaR21AI094402 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2012 to 2013
$484k
Development of simianized mice to study the biology of relapsing malaria parasitesR21AI135711 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2018 to 2019
$482k
NIAID NIH HHS R21 AI094402NIAID NIH HHS R21 AI135711NIAID NIH HHS R56 AI103382NIH HHS P51 OD011132
6 · The paper itself

Abstract

Malaria control and interventions including long-lasting insecticide-treated nets, indoor residual spraying, and intermittent preventative treatment in pregnancy have resulted in a significant reduction in the number of

Indexed as

Antibody FormationAnimalsAntibodies, ProtozoanAntigens, ProtozoanAntigens, SurfaceChromobox Protein Homolog 5Disease Transmission, InfectiousMalaria VaccinesMalaria, VivaxMerozoite Surface Protein 1MicePlasmodium vivaxRecombinant Fusion ProteinsTime FactorsVaccines, SyntheticAntibodies, ProtozoanAntigens, ProtozoanAntigens, SurfaceCBX5 protein, humanChromobox Protein Homolog 5Malaria VaccinesMerozoite Surface Protein 1Pvs25 protein, P vivaxRecombinant Fusion ProteinsVaccines, Syntheticchimeric vaccinemalariamulti-stageP25Plasmodium vivaxtransmission-blocking

Identifiers

PMID31119106
PMCPMC6504793
OpenAlexW2943480486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.